NDATOPICALCREAM
Approved
Jun 1984
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
19
Data completeness
4/8 — Partial
ALPHATREX (betamethasone dipropionate) by Sandoz is [see ] . Approved for psoriasis, atopic dermatitis. First approved in 1984.
Drug data last refreshed 20h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ALPHATREX is a topical corticosteroid cream containing betamethasone dipropionate, approved in 1984 for treating psoriasis and atopic dermatitis. The drug modulates immune function and reduces inflammation through corticosteroid mechanisms, though the precise mechanism for dermatologic indications remains incompletely characterized. It is a mature, generic-accessible treatment in the topical dermatology space.
LOE Approaching
As an approaching LOE product with minimal linked job activity, ALPHATREX represents a declining commercial priority with limited team expansion opportunities.
Mechanism of Action
[see ] . Betamethasone dipropionate is a corticosteroid. Corticosteroids play a role in cellular signaling, immune function, inflammation, and protein regulation; however, the precise mechanism of action for the treatment of tinea pedis, tinea cruris and tinea corporis is unknown.
Indications (2)
Worked on ALPHATREX at Sandoz? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.